Our Company

Aspiring to be the global leader in DDR-targeted cancer therapies

Our Focus

Aprea Therapeutics Inc., (NASDAQ: APRE) is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response (DDR) pathways.

Our Leadership

We have assembled an outstanding team, which includes world class scientific and clinical oncology leaders, to execute on our mission to create novel DDR-targeted cancer therapies. Together with our board of directors, our scientific founders and members of our management team have significant experience in drug discovery and development and finance. Collectively, we believe our team’s strong capabilities position us to build a leading biotech company focused on developing novel cancer therapies to address the significant unmet medical need of patients with cancer.

Management Team

Oren Gilad, Ph.D.

President and Chief Executive Officer

Oren Gilad, Ph.D., has served as our Chief Executive Officer since July 2022 and as President and a member of our board of directors since May 2022. He previously served as President and CEO of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea. He brings extensive experience across multiple phases of drug development. Prior to founding Atrin in 2011, Dr. Gilad authored several high impact scientific publications over the course of a 13 year academic career, including demonstration of the importance of the ATR pathway in cancer development and treatment. Dr. Gilad holds a Ph.D from University of California at Davis and a B.Sc from the Hebrew University.

Scott M. Coiante

Senior Vice President and Chief Financial Officer

Scott M. Coiante has served as our Senior Vice President, Chief Financial Officer since August 2019. Mr. Coiante joined Aprea from Agile Therapeutics, or Agile, where he was Senior Vice President and Chief Financial Officer. Having served at Agile since 2010, he played a leadership role in the company and in the development of the internal finance and accounting infrastructure. Prior to joining Agile, he was from 2002 Vice President of Finance and Treasurer at Medarex, Inc., formerly a NASDAQ listed biotech company that was acquired in 2009 by Bristol Myers Squibb. From 1989 to 2002, Mr. Coiante held management positions of increasing responsibilities at Ernst & Young LLP. Mr. Coiante received a B.S. in Accounting from Villanova University.

Gregory A. Korbel, Ph.D.

Senior Vice President and Chief Operating Officer

Gregory A. Korbel., Ph.D. has served as our Chief Operating Officer since May 2022, having previously served as Chief Business Officer since March 2021 and Vice President, Business Development since July 2016. Dr. Korbel has more than 14 years of experience in the biotechnology and pharmaceutical industries. Prior to joining Aprea Therapeutics, he was Director of Business Development and Operations at Novira Therapeutics, which was acquired in December 2015 by Johnson & Johnson, and served as Director of Research Operations subsequent to the acquisition. In addition to consulting for venture capital and biotechnology firms, he formerly served as Senior Scientist at Invtirogen/Life Technologies. Dr. Korbel received an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in Chemistry from Harvard University and a B.A. from Vanderbilt University.

Ze’ev Weiss, CPA, B.Sc.

Chief Business Officer

Ze’ev Weiss, CPA, B.Sc., has served as our Chief Business Officer since May 2022. Ze’ev brings over 20 years of broad and extensive biopharmaceuticals industry experience in strategic, operational, and corporate development in the emerging and established healthcare industry. Until 2017, Ze’ev served as the CEO and formerly as Executive VP Commercial Operations of Intec Pharma (NASDAQ: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill® platform technology. He successfully led Intec’s IPO on NASDAQ as well as multiple collaboration agreements with global leading pharmaceutical companies. Ze’ev also had a central role in leading Intec from their very early stage into late clinical stage, including financing, pre-clinical and clinical development, regulatory and intellectual property activities. Prior to Intec, Ze’ev was Head of Life Sciences Strategic Consulting at PricewaterhouseCoopers, Israel. At PwC, he led numerous corporate developments, business development, strategic planning and corporate finance consulting engagements with various healthcare companies. Ze’ev holds a BA in accounting and is a certified public accountant. He also earned a B.Sc in Biology and has completed M.Sc. in Neuro-Biochemistry studies from Tel Aviv University, Israel.

Board of Directors

Oren Gilad, Ph.D.

President and Chief Executive Officer

Oren Gilad, Ph.D., has served as our Chief Executive Officer since July 2022 and as President and a member of our board of directors since May 2022. He previously served as President and CEO of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea. He brings extensive experience across multiple phases of drug development. Prior to founding Atrin in 2011, Dr. Gilad authored several high impact scientific publications over the course of a 13 year academic career, including demonstration of the importance of the ATR pathway in cancer development and treatment. Dr. Gilad holds a Ph.D from University of California at Davis and a B.Sc from the Hebrew University.

Christian S. Schade

Executive Chairman of the Board

Christian S. Schade has served as Executive Chairman of the board of directors since July 2022. Mr. Schade previously served as President and Chief Executive and as a member of our board of directors since June 2016, and was appointed Chairman of the board of directors in September 2020. Mr. Schade has more than 30 years of public and private pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in investment banking. Prior to joining Aprea, Mr. Schade was Chief Executive Officer of Novira Therapeutics Inc., a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson. He also served as Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceuticals company until it was purchased by AstraZeneca Plc. He previously held executive level positions at NRG Energy, serving as Executive Vice President and Chief Financial Officer, and as Senior Vice President Administration and Chief Financial Officer at Medarex Inc., until it was acquired by Bristol-Myers Squibb Co. He also held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade currently serves on the Board of Directors of Integra Life Sciences (NASDAQ: IART) where he chairs the Finance Committee, and on the Board of Directors of Sapience Therapeutics, a privately held company. He received an A.B. degree from Princeton University, and an M.B.A. from the Wharton School at the University of Pennsylvania.

Marc Duey

Director

Marc Duey has served as a member of our board of directors since May 2022 and previously served on the board of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea. He brings over three decades of experience in the pharmaceutical and biotechnology industries. Mr. Duey is the Founder, President and CEO of ProMetrics Inc. Prior to founding ProMetrics, Mr. Duey was founder and President of DuWest Research, an international management consulting firm for diagnostic and biotechnology companies. He serves on the Board of Trustees of International House Philadelphia and is a member of the Leadership Council of the Wistar Institute. He is an active member of the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the American Association of Pharmaceutical Science (AAPS), and the Licensing Executive Society (LES). Mr. Duey holds a B.S. and an M.S. degree in science from the University of Ottawa, and an M.B.A. from the Ivey Business School at Western University, London, Canada.

John B. Henneman

Lead Independent Director

John B. Henneman III has served as a member of our board of directors since August 2019 and was appointed Lead Independent Director in September 2020. Mr. Henneman has more than 25 years of combined financial and operational management experience in the life sciences industry. From July 2018 until November 2018, Mr. Henneman served as the Chief Administrative Officer of NewLink Genetics Corporation, a biotechnology company, and prior to that, served as NewLink’s Executive Vice President and Chief Financial Officer from October 2014 to July 2018. From 1998 to 2014, Mr. Henneman served at Integra LifeSciences Holdings Corp., a publicly-held medical device company, in various capacities. Before becoming Integra’s Chief Financial Officer in 2007, Mr. Henneman was Chief Administrative Officer, responsible for Integra’s regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions, the management of Integra’s surgical instruments business, and Integra’s business development function. Mr. Henneman serves on the boards of directors of R1 RCM, Inc., a publicly-held revenue cycle technology and management services company, SeaSpine Holdings Corporation, a publicly-held medical technology company, and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm, and a consultant to SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies.

Michael Grissinger

Director

Michael Grissinger has served as a member of our board of directors since May 2022 and previously served on the board of directors of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea. Mr. Grissinger brings to Atrin extensive experience in business and corporate development, finance, marketing and strategic planning in the pharmaceutical industry. He spent 22 years at Johnson & Johnson, holding positions of Vice President and Head, Worldwide Pharmaceutical Licensing as well as Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. He has led transactions and teams across a broad span of deal types, geographies, and therapeutic areas. Prior to joining Johnson & Johnson, Mr. Grissinger spent 20 years in the healthcare industry with Ciba-Geigy and SmithKline Beckman. Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business.

Rifat Pamukcu, M.D.

Director

Rifat Pamukcu, M.D., has served as a member of our board of directors since May 2022 and previously served on the board of directors of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea. Dr. Pamukcu has extensive experience in pharmaceuticals and drug development, with a particular focus on oncology. He currently serves as the President and CEO of RxMP Therapeutics, Inc. He was also a co-founder, Director and CSO of Cell Pathways (NASDAQ:CLPA) until its acquisition by OSI Pharmaceuticals in 2003. Dr. Pamukcu has been a member of the Advisory Council to the National Prostate Cancer Coalition, the GI Oncology Task Force of the American Gastroenterological Association, Executive Steering Committee of the Gastroenterology Research Group and Scientific Advisory Board of the Hereditary Colon Cancer Association. He has authored or co-authored over 110 journal articles, book chapters and abstracts in the fields of gastroenterology, cancer, cancer chemoprevention and signal transduction systems and is an inventor on over 150 issued or pending patents in the areas of drug discovery and development of agents for cancer prevention and therapeutics, inflammatory bowel disease, osteoporosis and the prevention and treatment of hemorrhage. Dr. Pamukcu holds a B.A. in Biology from the John Hopkins University and an M.D. from the University of Wisconsin School of Medicine. He completed his Internal Medicine Residency at Rush Presbyterian St. Luke’s Medical Center and his Fellowship in Gastroenterology and Hepatology at the University of Chicago.

Richard Peters, M.D., Ph.D.

Director

Richard Peters, M.D., Ph.D. has served as a member of our board of directors since June 2020. Dr. Peters brings more than 25 years of experience developing new therapies for difficult-to-treat diseases. He currently serves as President, Chief Executive Officer and Director at Yumanity Therapeutics Inc. Dr. Peters joined Yumanity from Merrimack Pharmaceuticals, Inc. where he was President & Chief Executive Officer. Prior to Merrimack, he served as Senior Vice President and Head, Global Rare Diseases at Genzyme (Sanofi). Dr. Peters is a Harvard-trained physician and scientist, has served on the faculty at the Massachusetts General Hospital, and completed a Howard Hughes Medical Institute Fellowship in biophysics at Harvard Medical School. Dr. Peters commenced his medical studies at UC Louvain in Belgium and holds M.D. and Ph.D. degrees from the Medical University of South Carolina.

Bernd R. Seizinger, M.D., Ph.D.

Director

Bernd Seizinger, M.D., Ph.D., has served as a member of our board of directors since 2016. Dr. Seizinger currently serves as chairman/board member in a number of public and private biotech companies in the U.S., Europe and Canada, including: Oxford BioTherapeutics, Aprea, CryptoMedix, Oncolytics and BioInvent. Previously he was President & CEO of GPC Biotech; VP Oncology Drug Discovery and – in parallel – VP Corporate and Academic Alliances at Bristol-Myers Squibb; Executive VP and CSO, Genome Therapeutics; Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University.